Company intelligence / Profile preview

Shanghai Theorion Pharmaceutical

Shanghai, Shanghai Shi, Chinaglobaldata.com ↗

Ownership: Private
Development stage: Other

Overview

Shanghai Theorion Pharmaceutical Co., Ltd. was established in December 2015 and operates in the pharmaceutical industry with a focus on pharmaceutical intermediates, new drug R&D, biotechnology, and health technology. Its main known clinical asset is bisthianostat, an HDAC inhibitor targeting histone deacetylases for the treatment of multiple myeloma. There are no public results from advanced clinical trials as of early/mid–2025.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Originator organization for bisthianostat listed as Shanghai Puyi Chemical Co. Ltd.

Beyond the preview

Go deeper on Shanghai Theorion Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Theorion Pharmaceutical.

Explore the full profile